 The FDA has approved Cara Therapeutics Inc NASDAQ: CARA and Vifor Pharma AGs Korsuva difelikefalin injection for severe-to-moderate pruritis itching in patients with chronic kidney disease CKD undergoing dialysis. Difelikefalin is an opioid agonist that targets the kappa opioid receptor in the peripheral nervous system. 